TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32766885
Drug: Histidine supplementation
Normalized name: Histidine
DrugBank: Histidine (DB00117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Histidine supplementation at 12 g/d (Study 1)
Study: 32766885
Drug: Histidine supplementation
Normalized name: Histidine
DrugBank: Histidine (DB00117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Histidine supplementation at 16 g/d (Study 2)
Study: 32766885
Drug: Histidine supplementation
Normalized name: Histidine
DrugBank: Histidine (DB00117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Histidine supplementation (4, 8, and 12 g/d in Study 1)
Study: 32766885
Drug: Histidine supplementation
Normalized name: Histidine
DrugBank: Histidine (DB00117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Histidine supplementation (16 g/d in Study 2)
Study: 32766961
Drug: Low-dose ticagrelor
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ticagrelor
Study: 32768179
Drug: Bleeding leading
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleeding leading to a postoperative haemoglobin <70 g L
Study: 32769075
Drug: Videoconferencing and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Videoconferencing and self-administered tests of functional mobility and strength
Study: 32770263
Drug: CA6 rs17032907
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA6 rs17032907 gene variant (dominant model CC vs. TT)
Study: 32770263
Drug: Genotype CC
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype CC and allele C presence
Study: 32770704
Drug: Placement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placement of a rectal balloon catheter alongside the AAR catheter
Study: 32770720
Drug: Budigalimab at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budigalimab at 1, 3, or 10 mg/kg intravenously every 2 weeks (Q2W) in dose escalation; flat doses of 250 mg Q2W or 500 mg every four weeks (Q4W) in multihistology expansion cohort.
Study: 32770720
Drug: Budigalimab at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budigalimab at 1, 3, or 10 mg/kg intravenously every 2 weeks (Q2W) in dose escalation.
Study: 32770720
Drug: Budigalimab at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budigalimab at various doses.
Study: 32770845
Drug: Medication reconciliation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication reconciliation conducted by a pharmacist
Study: 32770954
Drug: Anti-TB chemotherapy
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TB chemotherapy
Study: 32771020
Drug: Robot-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted therapy (RT) intervention, eighteen 1-h sessions
Study: 32771088
Drug: Olaparib 300
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 300 mg orally twice daily for 4 weeks, followed by olaparib 300 mg twice daily and durvalumab 1.5 g intravenously every 4 weeks until disease progression.
Study: 32771088
Drug: Olaparib and
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib and durvalumab combination treatment.
Study: 32772323
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment (TTh) for 27.63 ± 3.64 weeks
Study: 32772323
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment (TTh)
Study: 32772769
Drug: CD19 CAR-T
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD19 CAR-T cells therapy
Study: 32773447
Drug: DaxibotulinumtoxinA for
Normalized name: daxibotulinumtoxinA-lanm
Approvals — FDA: no, EMA: no, PMDA: no
Description: DaxibotulinumtoxinA for Injection (DAXI) 40U, up to 3 treatments over a maximum of 84 weeks
Study: 32773474
Drug: Ritonavir-boosted darunavir
Normalized name: Darunavir
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir-boosted darunavir 800 mg once daily and etravirine 400 mg once daily or 200 mg twice daily
Study: 32774419
Drug: Comprehensive Spa
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive Spa Therapy using Therapeutic Radon-Sulfur Waters
Study: 32775974
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dimethyl sulfide and D-limonene
Study: 32776159
Drug: Methylphenidate hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate hydrochloride multilayer extended-release capsules (MPH-MLR) at doses of 10, 15, or 20 mg
Study: 32776489
Drug: Episodic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Episodic treatment (n=10)
Study: 32776489
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment (n=14)
Study: 32776489
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (aPCC and/or rFVIIa)
Study: 32776632
Drug: Trametinib 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trametinib 1.5 mg daily and Sorafenib 200 mg twice daily
Study: 32777064
Drug: Ixazomib (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixazomib (4 mg on days 1, 8, and 15 of a 28-day cycle, started on day +5)
Study: 32777116
Drug: Lenalidomide 25
Normalized name: lenalidomide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 25 mg/d for 21 days in combination with idarubicin and cytarabine chemotherapy
Study: 32777335
Drug: 24 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 Gy single-dose radiation therapy (SDRT)
Study: 32778095
Drug: Olaparib 300
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 300 mg BID followed by olaparib + durvalumab (1500 mg Q4W) + tremelimumab (75 mg IV Q4W) for 4 months, then durvalumab alone until progression or intolerable toxicity.
Study: 32779863
Drug: Anakinra (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (subcutaneous daily injections starting at 2 mg/kg, increased up to 6 mg/kg if fever persisted)
Study: 32780661
Drug: HFRT (43.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFRT (43.5 Gy in 15 fractions over 3 weeks with a boost of 8.7 Gy in three daily fractions)
Study: 32781527
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of gemcitabine with cisplatin
Study: 32781527
Drug: Inhibitor of
Normalized name: Membrane inhibitor of reactive lysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibitor of fibroblast growth factor receptor 2 (FGFR2)
Study: 32781527
Drug: Immunotherapeutic drugs
Normalized name: IMMUNOTHERAPEUTIC VACCINE CONSISTING OF (PAM)2-LYS-SER-SER-GLN-TYR-ILE-LYS-ALA-ASN-SER-LYS-PHE-ILE-GLY-ILE-THR-GLU-ALA-ALA-ALA-PHE-LEU-PRO-SER-ASP-PHE-PHE-PRO-SER-VAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapeutic drugs
Study: 32781541
Drug: R-CHOP (rituximab
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) plus IT-MTX (intrathecal methotrexate) 12 mg, six cycles of R-CHOP and four fixed doses of IT-MTX.
Study: 32782084
Drug: Amphetamine-type stimulant
Normalized name: AMPHETAMINE LIKE STIMULANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine-type stimulant positive patients
Study: 32782084
Drug: Amphetamine-type stimulant
Normalized name: AMPHETAMINE LIKE STIMULANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine-type stimulant negative patients
Study: 32786149
Drug: Corticosteroids and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids and/or tacrolimus treatment for rejection
Study: 32787797
Drug: Prostate cancer
Normalized name: Leuprolide Acetate 22.5mg Lyophilisate for suspension for injection [Prostate Cancer] with Diluent, Transfer Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostate cancer patients (various treatments: RP, EBRT, HIFU, CT, ADT, AS)
Study: 32788120
Drug: Individualised thromboprophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised thromboprophylaxis protocol with augmented LMWH dosing, anti-Xa measurements, and twice-weekly ultrasonography screening for DVT
Study: 32788205
Drug: TAK-164 (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-164 (a second-generation investigational antibody-drug conjugate comprised of a human anti-GCC mAb conjugated to DGN549)
Study: 32789591
Drug: Single-agent abemaciclib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent abemaciclib
Study: 32789591
Drug: Real-world single-agent
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real-world single-agent chemotherapy (capecitabine, gemcitabine, eribulin, or vinorelbine)
Study: 32790648
Drug: Oral nicotinamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nicotinamide riboside (NR) for 5 to 9 days
Study: 32791158
Drug: Injection pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection pressure monitoring during PNB
Study: 32791158
Drug: High flow
Normalized name: Blood Set High Flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flow rate (9.6 mL/min)
Study: 32791158
Drug: Overall injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall injection pressure monitoring
Study: 32791523
Drug: INSTI as
Approvals — FDA: no, EMA: no, PMDA: no
Description: INSTI as a third agent
Study: 32792226
Drug: Intrathecal recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal recombinant human arylsulfatase A (rhASA) at 10, 30, or 100 mg every other week for 38 weeks (n=6 per cohort)
Study: 32792226
Drug: Intrathecal recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal recombinant human arylsulfatase A (rhASA) at 100 mg (cohort 4, n=6)
Study: 32792226
Drug: Intrathecal recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal recombinant human arylsulfatase A (rhASA) at 100 mg
Study: 32792456
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy Sensory Instrument for Cognition, Consciousness and Awareness (MuSICCA)
Study: 32792991
Drug: Escitalopram treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram treatment after 12 weeks
Study: 32793403
Drug: Deferasirox film-coated
Normalized name: deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferasirox film-coated tablets (FCT)
Study: 32794142
Drug: Intravenous methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous methylphenidate (0.5-2.0 mg/kg)
Study: 32795349
Drug: Sintilimab plus
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab plus CapeOx (200 mg IV of sintilimab and 1000 mg/m2 of capecitabine and oxaliplatin)
Study: 32797064
Drug: Non-compacted LV
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-compacted LV mass (median 14.0 [interquartile range 12.6-16.0] g/m2)
Study: 32797101
Drug: Mass drug
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass drug administrations (MDAs) and reactive focal mass drug administrations (rfMDAs) with annual indoor residual spraying (IRS) and long-lasting insecticidal nets (LLINs)
Study: 32797101
Drug: Mass drug
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass drug administrations (MDAs)
Study: 32799036
Drug: Imatinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib treatment in frontline therapy
Study: 32799356
Drug: Extended duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended duration antibiotics
Study: 32800381
Drug: Tafamidis meglumine
Normalized name: Tafamidis meglumine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafamidis meglumine 20 mg/d
Study: 32800518
Drug: Tositumomab (TST)
DrugBank: Tositumomab (DB00081)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tositumomab (TST) and iodine-131 tositumomab (I-131 TST) followed by CHOP treatment
Study: 32800708
Drug: Intravenous antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antimicrobial exacerbation treatments
Study: 32800802
Drug: Definitive (chemo)radiation
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Definitive (chemo)radiation therapy for HPV-related OPC
Study: 32801289
Drug: Serum brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum brain natriuretic peptide ≥ 66.0 pg/mL
Study: 32802051
Drug: Dexmedetomidine (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (bolus dose over 15 min after delivery for parturient group)
Study: 32802051
Drug: Dexmedetomidine (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (bolus administered intravenously upon completion of spinal anesthesia for nonpregnant women group)
Study: 32802401
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg/day, vitamin D 2000 IU/day, GAD-alum 20 μg on D15 and D45
Study: 32802401
Drug: Placebo instead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo instead of Ibuprofen, vitamin D 2000 IU/day, GAD-alum 20 μg on D15 and D45
Study: 32802401
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg/day, vitamin D 2000 IU/day, GAD-alum 40 μg on D15 and D45
Study: 32802401
Drug: Placebo instead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo instead of Ibuprofen, vitamin D 2000 IU/day, GAD-alum 40 μg on D15 and D45
Study: 32802401
Drug: Ibuprofen, vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen, vitamin D + GAD-alum
Study: 32803633
Drug: Vantictumab plus
Normalized name: Vantictumab
DrugBank: Vantictumab (DB12956)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vantictumab plus weekly paclitaxel 90 mg/m
Study: 32804069
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Hypersomnia (CBT-H)
Study: 32804101
Drug: Pimavanserin (monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimavanserin (monotherapy or adjunctive therapy)
Study: 32804101
Drug: Pimavanserin (monotherapy)
DrugBank: Pimavanserin (DB05316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimavanserin (monotherapy)
Study: 32804101
Drug: Pimavanserin (adjunctive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimavanserin (adjunctive therapy)
Study: 32804590
Drug: Ripretinib 150
Normalized name: Ripretinib
DrugBank: Ripretinib (DB14840)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ripretinib 150 mg once daily (n = 142)
Study: 32805208
Drug: Levonorgestrel intrauterine
Normalized name: Levonorgestrel Intrauterine System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel intrauterine device (52 mg levonorgestrel, Mirena)
Study: 32806876
Drug: vedolizumab 108
Normalized name: VEDOLIZUMAB 108MG/0.68ML INJ PEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: vedolizumab 108 mg SC every 2 weeks
Study: 32806876
Drug: vedolizumab 300
Normalized name: vedolizumab 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: vedolizumab 300 mg IV every 8 weeks
Study: 32807090
Drug: nvHAP prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: nvHAP prevention bundle consisting of oral care, prevention of dysphagia-related aspiration, mobilization, stopping unnecessary proton pump inhibitors, and respiratory therapy.
Study: 32807456
Drug: Obesity and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obesity and previous use of antiplatelet therapy
Study: 32807717
Drug: High-dose weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose weekly carfilzomib, cyclophosphamide, and dexamethasone
Study: 32808163
Drug: Ivabradine 2.5-7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine 2.5-7.5 mg twice daily for 57 days
Study: 32809030
Drug: Magnetic Seizure
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnetic Seizure Therapy (MST) at low frequency (25 Hz)
Study: 32809030
Drug: Magnetic Seizure
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnetic Seizure Therapy (MST) at moderate frequency (50 or 60 Hz)
Study: 32809030
Drug: Magnetic Seizure
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnetic Seizure Therapy (MST) at high frequency (100 Hz)
Study: 32809030
Drug: Overall MST
Normalized name: MST 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall MST treatment
Study: 32809083
Drug: 3D printed
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3D printed brace for acute treatment of DRF
Study: 32809217
Drug: MK-1248 monotherapy
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-1248 monotherapy (starting dose 0.12 mg, maximum dose 170 mg)
Study: 32809217
Drug: MK-1248 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-1248 with pembrolizumab (200 mg) combination therapy (maximum dose 60 mg)
Study: 32809969
Drug: Baricitinib 4
Normalized name: baricitinib 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 4 mg twice daily for 2 days, followed by 4 mg per day for 7 days
Study: 32811969
Drug: Tocilizumab in
Normalized name: tocilizumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab in combination with methotrexate
Study: 32812818
Drug: Midostaurin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midostaurin plus chemotherapy
Study: 32812942
Drug: 30-g rapidly-digesting
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-g rapidly-digesting carbohydrate (RDC) drink consisting of maltodextrin and sucrose, administered after an 8-h fast.
Study: 32813194
Drug: PR-PFD (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: PR-PFD (600 mg bid)
Study: 32813884
Drug: Other stem
Normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other stem cell-based interventions (e.g. mononuclear cells, oligodendrocyte progenitor cells, neural stem cells, hematopoietic stem cells, and inducible pluripotent stem cells)
Study: 32814465
Drug: Clinically significant
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinically significant AA burden after treatment
Study: 32814465
Drug: AA burden
Approvals — FDA: no, EMA: no, PMDA: no
Description: AA burden after treatment
Study: 32816721
Drug: Oxfendazole oral
Normalized name: oxfendazole Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxfendazole oral suspension at 3, 7.5, and 15 mg/kg once daily for 5 days
Study: 32816721
Drug: Single 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 3 mg/kg dose of oxfendazole after overnight fast
Study: 32816721
Drug: Single 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 3 mg/kg dose of oxfendazole after consumption of a fatty breakfast
Study: 32816723
Drug: Fluconazole treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole treatment, dosage not specified, duration not specified
Study: 32816951
Drug: MEDI0562 (0.03,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI0562 (0.03, 0.1, 0.3, 1.0, 3.0, or 10 mg/kg) administered intravenously every 2 weeks until disease progression or unacceptable toxicity.
Study: 32816951
Drug: MEDI0562 (0.03,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI0562 (0.03, 0.1, 0.3, 1.0, 3.0, or 10 mg/kg) administered intravenously every 2 weeks.
Study: 32816955
Drug: Pooled alternative
Normalized name: HERBS/ALTERNATIVE THERAPIES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pooled alternative treatment to EFTR
Study: 32817060
Drug: CDKi as
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDKi as first-line treatment
Study: 32817060
Drug: CDKi as
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDKi as second-line treatment
Study: 32817060
Drug: CDKi as
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDKi as third-line treatment and beyond
Study: 32817060
Drug: CDKi treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDKi treatment
Study: 32817288
Drug: Rituximab (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (1,000 mg, two weeks apart) combined with belimumab (10 mg/kg at week 0, W0+2 days, W2+2 days, W4, W8, and W12)
Study: 32817593
Drug: H3.3K27M-targeted peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: H3.3K27M-targeted peptide vaccine administered with poly-ICLC every 3 weeks for 8 cycles, then every 6 weeks.
Study: 32817593
Drug: H3.3K27M-targeted peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: H3.3K27M-targeted peptide vaccine with observed immunological responses.
Study: 32817593
Drug: H3.3K27M-targeted peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: H3.3K27M-targeted peptide vaccine in patients with below-median baseline levels of myeloid-derived suppressor cells.
Study: 32817593
Drug: Immediate pretreatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate pretreatment dexamethasone administration.
Study: 32817978
Drug: High antibody
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High antibody level plasma units
Study: 32818157
Drug: Single full
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single full dose of penicillin
Study: 32819400
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume of 6.8 mL/kg
Study: 32819972
Drug: Ipilimumab 10
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 10 mg/kg every 3 weeks for four doses combined with radiotherapy (9, 15, 18, and 24 Gy) at week 4.
Study: 32819972
Drug: Ipilimumab 10
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 10 mg/kg every 12 weeks for maintenance after week 24 for patients with clinical benefit.
Study: 32819978
Drug: Insulin resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin resistance assessment